{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:39:26Z","timestamp":1768322366557,"version":"3.49.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["1S10RR26370"],"award-info":[{"award-number":["1S10RR26370"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.antiviral.2014.10.006","type":"journal-article","created":{"date-parts":[[2014,10,24]],"date-time":"2014-10-24T11:59:16Z","timestamp":1414151956000},"page":"80-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6053-8334","authenticated-orcid":false,"given":"Olga","family":"Latinovic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henryk","family":"Szmacinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph R.","family":"Lakowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alonso","family":"Heredia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert R.","family":"Redfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2014.10.006_b0005","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0952-7915(97)80135-5","article-title":"Immunoadhesins as research tools and therapeutic agents","volume":"9","author":"Ashkenazi","year":"1997","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.antiviral.2014.10.006_b0010","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/v6010054","article-title":"CCR5 as a natural and modulated target for inhibition of HIV","volume":"30","author":"Burke","year":"2013","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2014.10.006_b0015","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/nbt745","article-title":"A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes","volume":"20","author":"Cavrois","year":"2002","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2014.10.006_b0020","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/381667a0","article-title":"HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5","volume":"381","author":"Dragic","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2014.10.006_b0025","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1146\/annurev.biochem.70.1.777","article-title":"Mechanisms of viral membrane fusion and its inhibition","volume":"70","author":"Eckert","year":"2001","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.antiviral.2014.10.006_b0030","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0092-8674(00)81393-8","article-title":"CD4-independent infection by HIV-2 is mediated by Fusin\/CXCR4","volume":"87","author":"Endres","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2014.10.006_b0035","doi-asserted-by":"crossref","first-page":"11427","DOI":"10.1128\/JVI.74.24.11427-11436.2000","article-title":"Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120\u2013CD4 receptor complex","volume":"74","author":"Fouts","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.10.006_b0040","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1074\/jbc.273.8.4289","article-title":"Monocyte chemotactic protein-2 activates CCR5 and blocks CD4\/CCR5-mediated HIV-1 entry\/replication","volume":"273","author":"Gong","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2014.10.006_b0045","series-title":"Kucers\u2019 The Use of Antibiotics","first-page":"2869","article-title":"Maraviroc","author":"Gorry","year":"2010"},{"key":"10.1016\/j.antiviral.2014.10.006_b0050","doi-asserted-by":"crossref","first-page":"10411","DOI":"10.1073\/pnas.1834278100","article-title":"Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1","volume":"100","author":"Heredia","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2014.10.006_b0055","doi-asserted-by":"crossref","first-page":"11677","DOI":"10.1128\/JVI.79.18.11677-11684.2005","article-title":"Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism-2459 A\/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission","volume":"79","author":"Hladik","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.10.006_b0060","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1126\/science.1145373","article-title":"Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4","volume":"317","author":"Huang","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2014.10.006_b0065","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1124\/mol.107.035055","article-title":"CCR5 small-molecule antagonists and monoclonal antibodies exert potent synergistic antiviral effects by cobinding to the receptor","volume":"72","author":"Ji","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.antiviral.2014.10.006_b0070","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1128\/JVI.66.4.2232-2239.1992","article-title":"Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene","volume":"66","author":"Kimpton","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.10.006_b0075","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1128\/JVI.74.15.7005-7015.2000","article-title":"Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1","volume":"74","author":"Kuhmann","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.10.006_b0080","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0021-9673(01)87461-6","article-title":"Characterization of recombinant human interleukin-2 with micromethods","volume":"326","author":"Lahm","year":"1985","journal-title":"J. Chromatogr."},{"key":"10.1016\/j.antiviral.2014.10.006_b0085","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1097\/QAD.0b013e3283471edb","article-title":"Synergistic inhibition of R5 HIV-1 by Maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention","volume":"25","author":"Latinovic","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2014.10.006_b0090","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.virol.2010.12.029","article-title":"CCR5 antibodies HGS004 and HGS001 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells","volume":"411","author":"Latinovic","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2014.10.006_b9000","unstructured":"Latinovic, O., Zhang, J., Tagaya, Y., DeVico, A.L., Fouts, T.R., Schneider, K., Lakowicz, J.R., Heredia, A., Redfield, R.R., Synergistic inhibition of R5 HIV-1 by the fusion protein FLSC IgG1 Fc and Maraviroc in primary cells: Implications for prevention and treatment, submitted for publication."},{"key":"10.1016\/j.antiviral.2014.10.006_b0095","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1073\/pnas.96.9.5215","article-title":"Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages","volume":"96","author":"Lee","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2014.10.006_b0100","doi-asserted-by":"crossref","first-page":"9617","DOI":"10.1074\/jbc.274.14.9617","article-title":"Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function","volume":"274","author":"Lee","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2014.10.006_b0105","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0092-8674(00)80110-5","article-title":"Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection","volume":"86","author":"Liu","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2014.10.006_b0110","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/335181a0","article-title":"Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes","volume":"335","author":"Malim","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2014.10.006_b0115","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(05)63552-0","article-title":"CCR5-delta 32 gene deletion in HIV-1 infected patients","volume":"350","author":"Michael","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2014.10.006_b0120","doi-asserted-by":"crossref","first-page":"10598","DOI":"10.1073\/pnas.1932511100","article-title":"The entry of entry inhibitors: a fusion of science and medicine","volume":"100","author":"Moore","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2014.10.006_b0125","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1743-422X-9-84","article-title":"HIV taken by STORM: super-resolution fluorescence microscopy of a viral infection","volume":"9","author":"Pereira","year":"2012","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2014.10.006_b0130","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1128\/JVI.72.4.2855-2864.1998","article-title":"Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1","volume":"72","author":"Platt","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.10.006_b0135","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1128\/JVI.79.7.4357-4368.2005","article-title":"Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan","volume":"79","author":"Platt","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.10.006_b0140","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1128\/JVI.03447-13","article-title":"Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms","volume":"88","author":"Platt","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.10.006_b0145","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.virol.2008.04.032","article-title":"Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors","volume":"377","author":"Pugach","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2014.10.006_b0150","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jama.291.1.46","article-title":"Relationship between CCR5 density and viral load after discontinuation of antiretroviral therapy","volume":"291","author":"Reynes","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.antiviral.2014.10.006_b0155","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.1128\/JVI.00790-13","article-title":"Clustering and mobility of HIV-1 Env at viral assembly sites predict its propensity to induce cell\u2013cell fusion","volume":"87","author":"Roy","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.10.006_b0160","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nmeth929","article-title":"Stochastic optical reconstruction microscopy (STORM) provides sub-diffraction-limit image resolution","volume":"3","author":"Rust","year":"2006","journal-title":"Nat. Methods"},{"key":"10.1016\/j.antiviral.2014.10.006_b0165","doi-asserted-by":"crossref","first-page":"a006965","DOI":"10.1101\/cshperspect.a006965","article-title":"HIV transmission","volume":"2","author":"Shaw","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.antiviral.2014.10.006_b0170","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1074\/jbc.274.4.1905","article-title":"A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type I","volume":"274","author":"Siciliano","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2014.10.006_b0175","doi-asserted-by":"crossref","first-page":"21563","DOI":"10.1021\/jp3072876","article-title":"Large fluorescence enhancements of fluorophore ensembles with multilayer plasmonic substrates: comparison of theory and experimental results","volume":"116","author":"Szmacinski","year":"2012","journal-title":"J. Phys. Chem. C"},{"key":"10.1016\/j.antiviral.2014.10.006_b0180","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s12668-013-0076-7","article-title":"Imaging of protein secretion from a single cell using plasmonic substrates","volume":"3","author":"Szmacinski","year":"2013","journal-title":"Bionanoscience"},{"key":"10.1016\/j.antiviral.2014.10.006_b0185","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1126\/science.1241475","article-title":"Structure of the CCR5 chemokine receptor-HIV entry inhibitor Maraviroc complex","volume":"341","author":"Tan","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2014.10.006_b0190","doi-asserted-by":"crossref","first-page":"5460","DOI":"10.1128\/JVI.01049-07","article-title":"An alteration of human immunodeficiency virus gp41 leads to reduced CCR5 dependence and CD4 independence","volume":"82","author":"Taylor","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.10.006_b0195","doi-asserted-by":"crossref","first-page":"10645","DOI":"10.1128\/JVI.77.19.10645-10650.2003","article-title":"Nef does not affect the efficiency of human immunodeficiency virus type 1 fusion with target cells","volume":"77","author":"Tobiume","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.10.006_b0200","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1089\/aid.2006.22.477","article-title":"An immunoglobulin fusion protein based on the gp120\u2013CD4 receptor complex potently inhibits human immunodeficiency virus type 1 in vitro","volume":"22","author":"Vu","year":"2006","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.antiviral.2014.10.006_b0205","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1128\/JVI.02006-06","article-title":"Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist Maraviroc utilize inhibitor-bound receptor for entry","volume":"81","author":"Westby","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.10.006_b0210","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0079-6468(05)43007-6","article-title":"The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS","volume":"43","author":"Wood","year":"2005","journal-title":"Prog. Med. Chem."},{"key":"10.1016\/j.antiviral.2014.10.006_b0215","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1084\/jem.185.9.1681","article-title":"CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro","volume":"185","author":"Wu","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2014.10.006_b0220","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/31269","article-title":"Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development","volume":"393","author":"Zou","year":"1998","journal-title":"Nature"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214002861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214002861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T03:37:04Z","timestamp":1598413024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354214002861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":45,"alternative-id":["S0166354214002861"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.10.006","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}